We investigated the utility of computer simulation models for performance comparisons of different tumor marker assessment criteria to define progression or nonprogression of metastatic breast cancer. Methods: Clinically relevant values for progressive cancer antigen 15.3 and carcinoembryonic antigen concentrations were combined with representative values for background variations in a computer simulation model. Fifteen criteria for assessment of longitudinal tumor marker data were obtained from the literature and computerized. Altogether, 7200 different patients, each based on 50 measurements, were simulated. With a sampling interval of 4 weeks, the monitoring period for each event was ϳ3.8 years. Results: Modulation of the background variation, the starting concentrations, and the cutoffs enabled identification of criteria that were robust against false-positive signals of progression. Conclusions: The computer simulation model is a fast, effective, and inexpensive approach for comparing the diagnostic potential of assessment criteria during clinically relevant conditions of steady-state and progressive disease. The model systems can be used to generate tumor marker assessment criteria for a variety of malignancies and to compare and optimize their diagnostic performance.
The potential roles of the serological tumor markers cancer antigen 15.3 (CA 15.3) 5 and carcinoembryonic antigen (CEA) in monitoring patients with metastatic breast cancer have been the subject of several studies (1) (2) (3) . Their usefulness depends on their ability to identify, predict, and exclude tumor growth before the changes are detectable by other methods. The exact clinical applications, however, are still unclear because of uncertainty in the interpretation of sequential concentrations (4 ) . However, recent studies have suggested that the magnitude of any changes in concentration as well as the upper reference limits or other cutoff values should be integrated into tumor marker-based decision limits (5 ) . The purpose of the present study was to investigate whether computer simulation of CA 15.3 and CEA data could be used to compare the diagnostic performance of different criteria in terms of progression. Descriptive parameters of patient-related marker data were integrated into the simulation procedure according to the desired clinical and laboratory situation. Software programs for monitoring of tumor marker increments in breast cancer were developed on the basis of previously published assessment criteria. The criteria were compared in a variety of simulated conditions of steady-state and progressive disease.
Materials and Methods design of the database
The Corel Quattro Pro 8.0 software package was used for data generation and calculations. The first step was to generate four data sections with steady-state data. Each section comprised simulations of 100 different patients, each with 50 measurements. The data in all four sections were characterized by the same variability in terms of the total CV (CV T ), although the generated numbers differed among the simulated patients. In the next step, the steady-state data in three of the sections were combined with increasing values representing tumor growth.
criteria for monitoring sequential tumor marker concentrations
The algorithms were computerized and classified according to their characteristics as shown in Figs. 1-4 (5-13 ) . The criteria were based on at least two or three measurements; however, the maximum number of measurements and/or the maximum considered time span remained unreported. The increments associated with metastatic growth fulfilled criteria for progression among patients within ϳ6 months after exceeding the baseline value (5, 14 ) . For the sake of comparison, the observation window for each criterion used in the simulation model was therefore set to ϳ6 months (28 weeks). The tested concentration, which represented either the latest or the second latest determination, was compared with a maximum of seven or six previous concentrations, respectively. The observation window then moved to the next measurement, which now became the latest, and the first measurement from the previous observation period was disregarded. The procedure was repeated until all 50 marker determinations were scanned for progression by the respective criteria.
The criteria developed by Sölétormos et al. (5 ) differed from the others because the assessment procedure (a) involved two sets of criteria for CA 15.3 and CEA concentrations, one set to identify slow rise and another to identify fast rise kinetics; (b) considered whether concentrations started below or above the cutoff value; (c) integrated the cutoff value in the procedure for assessment of below-cutoff concentrations; and (d) ensured that an increment was significant before it was interpreted as indicative of progression. Accordingly, a change was significant if the difference, expressed as a percentage of the mean value, exceeded ͌2 ⅐ Z ⅐ CV T (15 ) , where ͌2 is Points connected by dashed lines indicate measurements that are not necessarily consecutive. Points connected by solid lines indicate consecutive measurements. CD, required critical difference. ‫,ء‬ recommended cutoff; ‫,ءء‬ recommended cutoff ϫ 3.8 (Table 1) .
(A), the criterion is based on at least two measurements. The latest concentration, which is below or above the recommended cutoff, is at least 25% higher than any previous concentration below cutoff [Dnistrian et al. (6 ) ].
(B), the criterion is based on two consecutive measurements. The latest concentration is above and the second latest is below the recommended cutoff without requirements for the magnitude of the difference in concentrations [Barak et al. (7 )].
(C), the criterion is based on at least two measurements. The latest concentration is above the recommended cutoff and at least 25% higher than any previous concentration below cutoff [Tondini et al. (8 ) ].
(D), the criterion is based on at least two measurements. The latest concentration is above the recommended cutoff and is twice that of any previous concentration below cutoff [Sölétor-mos et al. (5 ) ].
(E), the criterion is based on at least two measurements. The latest concentration is 3.8 ϫ above the recommended cutoff and significantly higher than any previous concentration below cutoff [Sölétormos et al. (5 ) ].
a constant (for two measurements) and the Z-statistic depends on the probability selected for significance and on whether the expected change is uni-or bidirectional. A unidirectional change (increment) was expected if concentrations were increased at a steady state or were below the cutoff value; Z ϭ 1.65 for P Ͻ0.05. CV T was equal to the average within-subject total variation determined among healthy females and comprised the analytical imprecision and the within-subject biological variation, ϳ13% for CA 15.3 and CEA (16 ) .
simulation of cutoffs and starting concentrations
The performance of criteria at different concentrations and cutoffs was investigated by changing the cutoff/ starting concentration ratio. The ratio standardized the Solid lines between points indicate consecutive measurements. Points connected by dashed lines indicate measurements that are not necessarily consecutive. CD, critical difference between concentrations; ‫,ء‬ recommended cutoff; ‫,ءء‬ recommended cutoff ϫ 2 (Table 1) .
(A), the criterion is based on three consecutive measurements and two consecutive increments without requirement for the magnitude of the difference in concentrations. The third latest concentration is below the recommended cutoff. The second latest and the latest concentrations are below, above, or on different sides of the recommended cutoff [Bonfrer (9 ) ].
(B), the criterion is based on at least three measurements. The latest concentration is higher than the second latest concentration without requirements for the magnitude of the difference. The second latest concentration is at least 25% higher than any previous concentration below the recommended cutoff. The second latest and the latest concentrations are below, above, or on different sides of the recommended cutoff [Bonfrer (9 ) ].
(C), the criterion is based on three consecutive measurements and two consecutive increments. The latest concentration is at least 12% higher than the second latest concentration. The second latest concentration is at least 12% higher than the third latest concentration. The third latest concentration is below the recommended cutoff. The second latest and the latest concentrations are below, above, or on different sides of the recommended cutoff [Mughal et al. (10 ) ].
(D), the criterion is based on three consecutive measurements. The latest and the second latest concentrations are above and the third latest concentration is below the recommended cutoff. The latest concentration is at least 30% higher than the second latest concentration. There is no requirement for the magnitude of the difference between the second and the third latest concentrations [Nicolini et al. (11 ) ].
(E), the criterion is based on three consecutive measurements. The latest and second latest concentrations are above and the third latest concentration is below two times the recommended cutoff. The latest concentration may be higher, equal to, or lower than the second latest concentration. There is no requirement for the magnitude of the difference between the second and the third latest concentrations [Molina et al. (12 ) ].
(F), the criterion is based on at least three consecutive measurements. The latest and the second latest concentrations are above the recommended cutoff. The latest concentration is higher than the second latest concentration, and the second latest concentration is higher than the third latest concentration. There is no requirement for the magnitude of the difference between the latest and the second latest concentrations. The second latest concentration is significantly higher than the third latest or any previous concentration below cutoff [Sölétormos et al. (5 ) ].
(G), the criterion is based on three consecutive measurements. The latest and second latest concentrations are above and the third latest concentration is below the recommended cutoff. The latest concentration may be higher, equal to, or lower than the second latest concentration. There is no requirement for the magnitude of the difference between the second and the third latest concentrations [Chan et al. (13 ) ].
number of times the cutoff value exceeded a given starting concentration ( Table 1) .
variation of steady-state concentrations
The CV T s of the generated data represented the 5th, 50th, and 95th centiles of variations observed among metastatic breast cancer patients (14 ) . The CV T comprised the analytical imprecision and the within-subject biological variation and was higher below than above the cutoff. For concentrations below the cutoff, the steady-state CV T s for CA 15.3 and CEA were 8.5% (5th centile), 15% (50th centile), and 36% (95th centile). Above cutoff, the CV T s were 3.1% (5th centile), 7.9% (50th centile), and 17% (95th centile).
simulation of patients in steady state
Recent clinical studies have suggested a gaussian distribution of steady-state tumor marker data; however, unusually large increments may occur (16 ) . Therefore, the generated numbers, which represented natural logarithmic data with a mean value of zero and a gaussian distribution, were transformed to a log-gaussian distribution. The procedure made the steady-state concentrations unitless with a mean of 1.0 for all individuals. Keeping a low mean value of the gaussian-distributed numbers facilitated specification of the magnitude of the desired fluctuations by the standard deviation of natural logarithm values instead of the CV of concentration data because they were nearly identical for small values (Ͻ0.15) and close for moderate values (up to ϳ0.30) (17, 18 ) . To ensure that the first value was below the cutoff point when the lowest cutoff/starting concentration ratio of 1.1 (Table 1) was applied, all values were set to start at 1.099.
rate of increase of progressive concentrations
The rates of the increases in CA 15.3 and CEA per day attributable only to tumor growth, without contribution from background variation, that are characteristic for metastatic breast cancer have been provided as natural logarithm-transformed data (14 ) . The rate constants were 0.0083 (5th centile), 0.0210 (50th centile), and 0.0706 (95th centile).
simulation of patients with progression
The natural logarithm-based rate constants were transformed to exponential functions and added to the normalized steady-state concentrations. To ensure a low starting point with a reasonable increase for even the slowest rate constants, the starting addition of marker from the tumor was set to 10% of the normalized mean.
performance comparison of assessment criteria
The performance parameters of the criteria were (a) the cumulated false-positive fraction, which denoted the cumulated number of events with at least one increment falsely interpreted as progression during steady state; (b) the cumulated true-positive fraction, which denoted the cumulated number of progressive events with at least one increment interpreted as progression; and (c) the measurement number that corresponded to either the cumulated false-positive or true-positive fraction. The princi- Points connected by dashed lines indicate measurements that are not necessarily consecutive. CD, required critical difference between concentrations. ‫,ء‬ recommended cutoff (see Table 1 ).
(A), the criterion is based on at least two measurements. The latest concentration is at least 25% higher than any previous concentration above the recommended cutoff [Dnistrian et al. (6 ) ].
(B), the criterion is based on at least two measurements. The latest concentration is significantly higher than any previous concentration above the recommended cutoff [Sölétormos et al. (5 )].
(C), the criterion is based on at least two measurements. The latest concentration is twice that of any previous concentration above the recommended cutoff [Sölétormos et al. (5 ) 
Results

performance of assessment criteria when tumor marker concentrations started in the middle of the reference interval
Performance for the CA 15.3-CEA data is shown in Table  2 . The background variation had considerable influence on the frequency of false-positive signals because larger fluctuations pushed the increase above the cutoff value. For the criterion in Fig. 2A , the susceptibility to fluctuations was independent of background variation because the criterion considered neither a critical difference nor a cutoff value. The ability to detect true-positive signals of progression depended on the rate of marker increase, the required critical difference, and the applied cutoff value. Progressive concentrations with a slow rate of increase were detected earlier if the required difference was small and the cutoff value was low. At medium and fast rate constants, the increments were so large that any of the required changes were reached early. The background variation had little influence on the frequency of truepositive signals because almost all criteria identified 100% of progressions irrespective of the CV T . The background variation, however, influenced the time of detection of marker progression, especially for slow rate constants. Marker kinetics with faster rate constants were influenced less by background fluctuations. The two consecutive increments required in Fig. 2A were mostly delayed because the criterion derived no advantage from larger increments. The CV T -induced smaller increments were still large enough to meet the required change in Fig. 1A within the accepted time interval, whereas the change required in Fig. 2F was not always met.
The criterion in Fig. 2D was the only criterion where the background variation influenced the frequency of true-positive signals. At slow rate constants and low CV T values, none of the progressing concentrations increased by 30%, whereas some exceeded the critical difference at Solid lines between points indicate consecutive measurements. Points connected by dashed lines indicate measurements that are not necessarily consecutive. CD, required critical difference between concentrations. ‫,ء‬ recommended cutoff (see Table 1 ).
(A), the criterion is based on three consecutive measurements and two consecutive increments above the recommended cutoff without requirements for the magnitude of the difference in concentrations [Bonfrer (9 ) ].
(B), the criterion is based on at least three measurements. The latest concentration is higher than the second latest concentration without requirements for the magnitude of the difference. The second latest concentration is at least 25% higher than any previous concentration above the recommended cutoff [Bonfrer (9 ) ].
(C), the criterion is based on three consecutive measurements and two consecutive increments above the recommended cutoff. The latest concentration is at least 12% higher than the second latest concentration. The second latest concentration is at least 12% higher than the third latest concentration [Mughal et al. (10 ) ].
(D), the criterion is based on at least three consecutive measurements. The latest concentration is higher than the second latest concentration, and the second latest concentration is higher than the third latest concentration. There is no requirement for the magnitude of the difference between the latest and the second latest concentrations and between the second and the third latest concentrations. The latest concentration is significantly higher than the third latest or any previous concentration above the recommended cutoff [Sölétormos et al. (5 )].
higher CV T values. At medium rate constants and low CV T values, several of the increments exceeded the required difference of 30%. The frequency of true-positive signals diminished with a higher CV T because several increments were impeded by more fluctuations and because the CV T -induced increments did not exceed the required change. At fast rate constants and low CV T values, the critical difference of 30% was easily met. A few fluctuations associated with a higher CV T were large enough to reduce the increment to below 30%.
performance of assessment criteria when tumor marker concentrations started high vs low in the reference interval All criteria subjected to further investigation for robustness against false-positive signals integrated a cutoff value in the assessment procedure (Table 3) . Three criteria remained free of false-positive CA 15.3-CEA signals. Assessment criteria based on higher cutoff concentrations ( Fig. 1E and Fig. 2E ) allowed fewer false positives than those with lower concentrations (Fig. 2, F and G) . All false progressions were obtained when marker concentrations fluctuated in the high end of the reference interval, and the frequency of false signals increased with larger fluctuations. The criterion in Fig. 2D remained robust against false-positive information even at a low cutoff concentration because an increase from below to above cutoff was confirmed by a consecutive large (30%) increment. When the starting value was lowered, the progressing concentrations rose more steeply with smaller fluctuations when they left the reference interval; however, detection was delayed because the time needed to reach the cutoff was extended. The criterion in Fig. 2F did not detect all progressions if concentrations started high in the reference interval because they increased too slowly after crossing the cutoff to meet the required critical difference within the accepted time limit. An unexpected result was that the criterion in Fig. 2F at high CV T signaled CA 15.3-CEA progression more frequently for steady-state concentrations that started just below cutoff and continuously fluctuated across the cutoff than for concentrations with a slow rate of increase (0.0083). The progressing concentrations had fewer below-cutoff fluctuations with fewer starting points for tumor marker assessment when compared with the steady-state fluctuations. For each simulated event, the investigated algorithm was applied to the concentration values in sequence of increasing sample number. The first time the requirement for progression was fulfilled, the event was considered positive at this sample number. The first positive signal of progression was cumulated from all events. For the sake of clarity and space, only data obtained from the first 20 measurements are shown. The positives (%) cumulated from events with a rate constant of 0.0000 represented the false-positive signals of progression, and those cumulated from events with rate constants of 0.0083, 0.0210, and 0.0706 represented the true-positive signals of progression. A cumulated positive fraction of 50% means that one-half of the events were recorded as positive at that time, and 1.0 means that all patients fulfilled the specified criterion for progression. In the example, 23% of steady-state events were falsely interpreted as progression. One hundred percent of events with a rate constant of 0.0083 were identified at the 19th measurement, and those with a rate constant of 0.0210 and 0.0706 at the 8th and 3rd measurement, respectively. Each simulated event comprised 50 measurements. With a sampling interval of 4 weeks, the monitoring period was 196 weeks (ϳ3.8 years). At a slow rate of CA 15.3-CEA increase, the criterion in Fig. 2D identified more true positives at high compared with low starting concentrations. Marker values that started high in the reference interval fluctuated several times across the cutoff, with more set points for starting concentrations and increased possibilities of meeting the specifications of the criterion than marker values with low starting concentrations that fluctuated across the recom- (10) 100 (4) 8. 5 Chan et al. (13 ) 0 (50) 100 (18) 100 (8) 100 (4) 15 ( Fig. 2G ) 0 (50) 100 (18) 100 (9) 100 (4) 36 0 (50) 100 (19) 100 (9) 100 (4) a Each of the 12 combinations of background variation and rate of increase comprises 100 simulated events with 50 concentrations per event. With a sampling interval of 4 weeks, the monitoring period was 196 weeks (ϳ3.8 years). Together, the 12 combinations represent 1200 patient events. The simulation procedure ensured different concentrations in each event. Within each combination, the assessment criteria were investigated on the same sets of data. The starting concentrations are provided in Table 1 . b CV T denotes the total background variation of CA 15.3-CEA concentrations, expressed as CV, and comprises the intra-and interassay analytical imprecision and the biological variation. The values 8.5%, 15%, and 36% denote the 5th, 50th, and 95th centiles of CV T values obtained among metastatic breast cancer patients with concentrations in a steady state below cutoff (14 ) . c Cumulated positive fraction denotes the fraction of events identified to have CA 15.3-CEA progression by the respective criteria. Measurement no. denotes the measurement number corresponding to the cumulated positive fraction. d The rates of increase in CA 15.3-CEA concentrations were calculated on the basis of natural logarithm-transformed data (14 ) . The rate constant 0.0000 denotes events where concentrations fluctuated in a steady-state condition according to the specified CV T value. The rate constants 0.0083, 0.0210, and 0.0706 were observed during tumor progression and denote the 5th, 50th, and 95th centiles of the rates of increase in concentrations observed among metastatic breast cancer patients (14 ) . (10) 100 (4) (Fig. 1E) 6.6 0 (50) 100 (25) 100 (11) 100 (4) (13) 100 (5) 8.5 Nicolini et al. (11 ) 1.1 0 (50) 0 (50) 2 (4) 100 (3) (Fig. 2D) 1.7 0 (50) 0 (50) 25 (7) 100 (4) (13) 100 (7) 100 (4) (Fig. 2F) 1.7 0 (50) 100 (18) 100 (7) 100 (4) mended cutoff within a shorter time interval. The reverse applied for medium and fast rate constants because most of the simulated patients showed steep tumor marker increases over consecutive increments by the time the tumor marker reached the cutoff from low starting concentrations.
performance of assessment criteria when tumor marker concentrations started above the reference interval
The performance for the CA 15.3-CEA data is shown in Table 4 . Background variation had a considerable effect on the frequency of false-positive signals among criteria based on a critical difference. The criterion in Fig. 3C supplied fewer false positives than the criterion in Fig. 3B because a doubling in concentrations was a greater requirement than a significant increment.
Discussion
Our data suggest a considerable potential for computer simulation models because a large variety of clinically relevant tumor marker kinetics can be simulated and the diagnostic ability of criteria can be compared. The ability to identify and exclude tumor marker progression depended on the characteristics of the individual criterion (the number of considered measurements, the required percentage of change, and the applied cutoff) and on the characteristics of the sequential data (the starting concentration, the background variation, and the rate of increase of progressing concentrations). Criteria that considered the cutoff value and adjusted the critical difference to the background variation of the investigated marker performed better than criteria where these parameters were not included. The model system was a fast approach for comparison of the diagnostic potential of assessment criteria. It took a few months to develop the model, but it would have taken a large multicenter study several decades to generate the same amount of data. The model was effective because the robustness against false-positive signals and the ability to detect progression could be determined in detail in a variety of situations. The computer simulation was also inexpensive: our only investment was $250 US for a 10-gigabyte hard drive, whereas measurements of CA 15.3 and CEA in a similar clinical trial would cost millions of US dollars.
Computer-aided test selection and result validation will undoubtedly become more integrated in clinical biochemistry (19 ) . However, in spite of the obvious advantages, this is the first tumor marker study based on simulated data. The reason is that the information necessary to generate clinically relevant models has only recently become available (14, 16 ) . All of the criteria compared in the present report have been used for patient (8) 100 (5) 100 (3) (Fig. 2G) 1.7 0 (50) 100 (15) 100 (7) 100 (4) (11) 100 (5) a Each of the 48 combinations of background variation, cutoff/starting concentration ratio, and rate of increase comprises 100 simulated events with 50 concentrations per event. With a sampling interval of 4 weeks, the monitoring period was 196 weeks (ϳ3.8 years). Together, the 48 combinations represent 4800 patient events. The simulation procedure ensured different concentrations in each event. Within each combination the assessment criteria were investigated on the same sets of data. The starting concentrations specified by the respective cutoff/starting concentration ratios are provided in Table 1 . b CV T denotes the total background variation of CA 15.3-CEA concentrations, expressed as CV, and comprises the intra-and interassay analytical imprecision and the biological variation. The values 8.5%, 15%, and 36% denote the 5th, 50th, and 95th centiles of CV T values obtained among metastatic breast cancer patients with concentrations in a steady state below cutoff (14 ) . (14 ) . The rate constant 0.0000 denotes events where concentrations fluctuated in a steady-state condition according to the specified CV T value. The rate constants 0.0083, 0.0210, and 0.0706 were observed during tumor progression and denote the 5th, 50th, and 95th centiles of the rates of increase in concentrations observed among metastatic breast cancer patients (14 ) .
monitoring (5-13 ) ; however, it remains unknown how they perform under different conditions, i.e., another patient population with different (a) starting concentrations at the initiation of monitoring, (b) background fluctuations of the analytical and biological variation components, and (c) rates of marker increase during progression. Here we compared the criteria when the above-mentioned parameters were standardized and changed according to the simulated clinical and laboratory situations. The study that provided the most detailed information on the diagnostic performance of the applied criteria as well as on the time interval for detection of progression was published by Sölétormos et al. (5 ) . The authors used the criteria in Fig. 1, D and F, for assessment of the CA 15.3-CEA concentrations that started above cutoff, and the criteria in Fig. 3C and Fig. 4D for belowcutoff starting concentrations. The date of marker progression was attributed to the algorithm that first signaled the progression. The criteria detected clinical progression with a median lead time of 36 days during first-line chemotherapy for metastatic breast cancer and 76 days during subsequent follow-up. We used the very same criteria in our simulations as a reference against which other criteria from the same authors as well as criteria from other authors were compared.
In reviewing the simulated below-cutoff data in Table  2 , the performance of the criteria in Fig. 1E (8) 100 (3) a Each of the 12 combinations of background variation and rate of increase comprises 100 simulated events with 50 concentrations per event. With a sampling interval of 4 weeks, the monitoring period was 196 weeks (ϳ3.8 years). Together, the 12 combinations represent 1200 patient events. The simulation procedure ensured different concentrations in each event. Within each combination, the assessment criteria were investigated on the same sets of data. b CV T denotes the total background variation of CA 15.3-CEA concentrations, expressed as CV, and comprises the intra-and interassay analytical imprecision and the biological variation. The values 3.1%, 7.9%, and 17% denote the 5th, 50th, and 95th centiles of CV T values obtained among metastatic breast cancer patients with concentrations in a steady state below cutoff (14 ) . c Cumulated positive fraction denotes the fraction of events identified to have CA 15.3-CEA progression by the respective criteria. Measurement no. denotes the measurement number corresponding to the cumulated positive fraction. d The rates of increase in CA 15.3-CEA concentrations were calculated on the basis of natural logarithm-transformed data (14 ) . The rate constant 0.0000 denotes events where concentrations fluctuated in a steady-state condition according to the specified CV T value. The rate constants 0.0083, 0.0210, and 0.0706 were observed during tumor progression and denote the 5th, 50th, and 95th centiles of the rates of increase in concentrations observed among metastatic breast cancer patients (14 ) .
closely below the cutoff, whereas the criterion in Fig. 2F [ Sölétormos et al. (5 ) ] provided false-positive information mainly for unusually large fluctuations (Table 3) .
In reviewing the above-cutoff data in Table 4 , the three criteria that supplied false-positive CA 15.3-CEA concentrations less frequently were those provided in Fig. 3C [Sölétormos et al. (5 )], Fig. 4C [Mughal et al. (10 ) ], and Fig. 4D [Sölétormos et al. (5 ) ]. However, identification of progression was delayed for several months with the criterion in Fig. 4C [Mughal et al. (10 ) ] compared with the criteria in Fig. 3C and Fig. 4D [Sölétormos et al. (5 ) ]. The criteria in Fig. 3C and Fig. 4D [Sölétormos et al. (5 ) ] provided false-positive information mainly for unusually large fluctuations.
Overall, the criteria developed by Sölétormos et al. (5 ) , as shown in Fig. 2F and Fig. 4D , performed best because signals of progression were detected early; however, sequential concentrations with unusually large fluctuations should be interpreted with caution. Thus, computersimulated data should be used to investigate whether the criteria can be further optimized without delaying detection of early signals of tumor growth. We hypothesize that assessment of sequential marker concentrations should be more differentiated than hitherto recognized. It may not suffice to base interpretation on concentrations being within or above the reference interval. Assessment of data within the normal range should probably depend on the baseline concentrations.
In conclusion, our results suggest that the simulation model presented here may be applied to the development of new tumor marker assessment criteria and to optimize already existing criteria. Assessments of sequential data probably will benefit from a differentiated approach where different criteria are combined depending on the baseline concentrations. When data defining steady-state variability and rates of increase are available, the model systems could be applied to malignancies other than breast cancer.
